Methods for enhancing hematopoietic stem/progenitor cell engraftment
US-9737567-B2 · Aug 22, 2017 · US
Methods for enhancing hematopoietic stem/progenitor cell engraftment
US10159697B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10159697-B2 |
| Application number | US-201715651416-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 17, 2017 |
| Priority date | Feb 3, 2009 |
| Publication date | Dec 25, 2018 |
| Grant date | Dec 25, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using farnesyl compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to an individual undergoing cell transplantation.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for enhancing hematopoietic cell engraftment in a subject following hematopoietic cell transplantation, the method comprising: administering to a subject following hematopoietic cell transplantation a therapeutically effective amount of a compound selected from the group consisting of: 2-chloro-5-farnesylaminobenzoic acid (NFCB), (farnesylthio)propanoic acid (FTP), and farnesyl acetate, wherein the level of engraftment of said hematopoietic cells in said subject treated with 2-chloro-5-farnesylaminobenzoic acid (NFCB), and/or (farnesylthio)propanoic acid (FTP), and/or farnesyl acetate is increased compared to engraftment of a population of hematopoietic cells in an untreated subject. 2. The method of claim 1 , wherein the compound is 2-chloro-5-farnesylaminobenzoic acid (NFCB). 3. The method of claim 1 , wherein the compound is (farnesylthio)propanoic acid (FTP). 4. The method of claim 1 , wherein said population of hematopoietic cells is derived from cord blood. 5. The method of claim 1 , wherein said population of hematopoietic cells is derived from bone marrow. 6. The method of claim 1 , wherein said population of hematopoietic cells is derived from blood. 7. The method of claim 1 , wherein said population of hematopoietic cells are isolated cells. 8. The method of claim 1 , wherein said population of hematopoietic cells is a heterogeneous or homogeneous population of cells. 9. The method of claim 1 , wherein said subject is a human subject. 10. The method of claim 1 , wherein said hematopoietic cells are hematopoietic stem cells. 11. The method of claim 1 , wherein said hematopoietic cells are hematopoietic progenitor cells.
Assignees
Inventors
Classifications
of sulfoxy acids or sulfur analogues thereof · CPC title
Sulfur, selenium, or tellurium compounds, e.g. thiols · CPC title
- A61K31/221Primary
with compounds having an amino group, e.g. acetylcholine, acetylcarnitine · CPC title
Lipids · CPC title
Esters, e.g. nitroglycerine, selenocyanates · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10159697B2 cover?
- Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using farnesyl compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to an individual undergoing cell transplantation.
- Who is the assignee on this patent?
- Childrens Medical Center
- What technology area does this patent fall under?
- Primary CPC classification A61K31/221. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).